Some biotechs are lucky to have a single Phase 2 ready for this valuation, let alone a Phase 3 fully funded and own all the rights still.
One of 13 targets I believe we have ready for Phase 2 and now 3.
MEND is about fast tracking ARDs, CRS and Sepsis, and I think UK is on the cards.
Study partners for ARDs were also in Belfast/Ireland.
I do agree though a market update is overdue after all these announcements...and given the Australian situation, an update on the plan.
But also, we can see from FP study from April (Monash), also associated with Covid, there are things going on in the background.
Chart - CYP, page-47
-
- There are more pages in this discussion • 299 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $44.90M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 25.0¢ | $3.097K | 12.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29341 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 11015 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |